Please use this identifier to cite or link to this item:
Title: Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
Authors: SCHNEEWEISS, AndreasLOIBL, SibylleMAMOUNAS, Eleftherios P.MINCKWITZ, Gunter vonMANO, Max S.UNTCH, MichaelHUANG, Chiun-ShengRASTOGI, PriyaCONTE, Pier FrancoD'HONDT, VeroniqueREDONDO, AndresSTAMATOVIC, LjiljanaBONNEFOI, Herve R.SALGUERO, Hugo Raul CastroFISCHER, Hans HolgerWAHL, Tanya A.SONG, ChunyanBLOTNER, StevenTRASK, PeterGEYER, Charles E.
Citation: JOURNAL OF CLINICAL ONCOLOGY, v.37, n.15, suppl.S, 2019
Appears in Collections:

Comunicações em Eventos - FM/Outros
Outros departamentos - FM/Outros

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.